아미노글리코사이드 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 제품별, 투여 경로별, 용도별, 지역별, 부문별 예측(2025-2030년)

Aminoglycosides Market Size, Share & Trends Analysis Report By Product, By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,299,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,694,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,484,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

아미노글리코사이드 시장의 성장 및 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 아미노글리코사이드 시장 규모는 2030년까지 24억 5,000만 달러에 달할 것으로 예측됩니다.

시장은 2025-2030년 CAGR 4.34%를 보일 것으로 예측됩니다. 이러한 수요 증가가 기대되는 배경에는 항생제의 대량 사용으로 이어지는 동물 질병의 발생이 증가하고 있는 것이 있습니다.

그러나 중증 귀독성, 신독성, 신경근 차단 등의 부작용이 있기 때문에 아미노글리코사이드계 항생제의 배합률은 저하되어 시장 성장에 악영향을 미칠 것으로 예측됩니다. 게다가 특정 아미노글리코사이드계 항생제 사용에 대한 규제 당국의 불승인도 이 산업의 성장을 저하시키는 요인이 될 것으로 예상되고 있습니다.

아미노글리코사이드 시장 보고서 하이라이트

• 토브라마이신은 예측기간 동안 시장에서 큰 성장을 보일 것으로 예측됩니다. 강력한 아미노글리코사이드계 항생제인 토브라마이신은 그람음성균, 특히 녹농균에 대한 광역 스펙트럼의 유효성으로 세계의 아미노글리코사이드계 항생제 산업에서 중요한 역할을 하고 있습니다.
• 투여 경로에 근거해, 시장은 주사제, 사료, 유방내, 국소, 경구제로 분류되며, 2024년 시장 점유율은 26.73%로 시장을 리드했습니다.
• 피부 감염증은 예측 기간 중 가장 빠른 CAGR로 성장할 것으로 예측됩니다. 피부 감염증은 그 높은 유병률과 그람음성균 감염증 치료에 있어서 아미노글리코사이드의 유효성으로 인해 시장의 중요한 촉진 요인이 되고 있습니다.
• 북미의 아미노글리코사이드 의약품 산업은 2024년 세계 매출액 점유율의 37.60%를 차지했습니다. 이 큰 점유율은 북미에서 우세한 세균 감염과 수백만 명의 사람들에게 영향을 미치는 확립된 헬스케어 인프라에 기인하고 있습니다.

목차

제1장 조사 방법 및 범위

제2장 주요 요약

제3장 아미노글리코사이드 시장의 변수, 동향 및 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련 및 부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 아미노글리코사이드 시장 분석 툴
  • 산업 분석-Porter's Five Forces 분석
  • PESTEL 분석
  • 가격 분석
  • 파이프라인 분석

제4장 아미노글리코사이드 시장 : 제품별 추정 및 동향 분석

• 세계의 아미노글리코사이드 시장 : 제품별 대시보드
• 세계의 아미노글리코사이드 시장 : 제품별 변동 분석
• 세계의 아미노글리코사이드 시장 : 제품별 및 수익별
• 네오마이신
• 토브라마이신
• 겐타마이신
• 아미카신
• 파로모마이신
• 스트렙토마이신
• 카나마이신
• 기타

제5장 아미노글리코사이드 시장 : 투여 경로별 추정 및 동향 분석

• 세계의 아미노글리코사이드 시장 : 투여 경로별 대시보드
• 세계의 아미노글리코사이드 시장 : 투여 경로별 변동 분석
• 세계의 아미노글리코사이드 시장 : 투여 경로별 및 수익별
• 주사제
• 사료
• 유방내
• 국소
• 경구

제6장 아미노글리코사이드 시장 : 용도별 추정 및 동향 분석

• 세계의 아미노글리코사이드 시장 : 용도별 대시보드
• 세계의 아미노글리코사이드 시장 : 용도별 변동 분석
• 세계의 아미노글리코사이드 시장 : 용도별 및 수익별
• 피부 감염증
• 요로 감염 및 골반 내 질환
• 수의사
• 호흡기 질환
• 기타

제7장 아미노글리코사이드 시장 : 치료, 치료 클래스, 투여 경로에 의한 지역별 추정 및 동향 분석

• 지역별 대시보드
• 시장 규모, 예측 및 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출 기업에 의한 최근의 동향 및 영향 분석
• 기업 및 경쟁의 분류
• 벤더 상황
  • 주요 리셀러와 채널 파트너 목록
  • 주요 기업의 시장 점유율 분석, 2024년
  • Pfizer Inc.
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd
  • Cipla
  • Sun Pharmaceutical Industries Ltd.
  • Lupin
  • Aurobindo Pharma Limited
  • Fresenius Kabi
  • Viatris Inc.

AJY

영문 목차

영문목차

Aminoglycoside Market Growth & Trends:

The global aminoglycosides market size is anticipated to reach USD 2.45 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 4.34% from 2025 to 2030. This expected growth in demand can be ascribed to the increasing incidences of animal disease outbreaks leading to high utilization of antibiotics.

However, reduction in prescription rate of aminoglycoside antibiotics due to side effects associated with usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade are expected to affect the market growth negatively. Furthermore, regulatory disapproval for the usage of certain aminoglycoside in regions is also anticipated to attribute for subordinate growth in this industry.

Aminoglycoside Market Report Highlights:

• Tobramycin is expected to exhibit significant growth in the market over the forecast period. It is a potent aminoglycoside antibiotic that plays a critical role in the global aminoglycosides industry due to its broad-spectrum efficacy against Gram-negative bacteria, particularly Pseudomonas aeruginosa.
• Based on route of administration, the market is categorized into injectable, feed, intra-mammary, topical, oral, and injectable, led the market with a market share of 26.73% in 2024.
• Skin infections are anticipated to grow at the fastest CAGR over the forecast period. Skin infections represent a significant driver for the market, owing to their high prevalence and the effectiveness of aminoglycosides in treating gram-negative bacterial infections.
• The North America aminoglycosides industry held 37.60% of the global revenue share in 2024. This large share is attributed to bacterial infections, which are dominant in North America, and a well-established healthcare infrastructure affecting millions of people.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Route of Administration
  • 1.2.3. Application
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and route of administration outlook
  • 2.2.2. Application outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Aminoglycosides Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of bacterial infections
    • 3.2.1.2. Advancements in drug development
    • 3.2.1.3. Growing awareness and diagnosis
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of development
    • 3.2.2.2. Regulatory challenges for new drug approvals
• 3.3. Aminoglycosides Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
  • 3.3.4. Pipeline Analysis
    • 3.3.4.1. Phase 1
    • 3.3.4.2. Phase 2
    • 3.3.4.3. Phase 2

Chapter 4. Aminoglycosides Market: Treatment Estimates & Trend Analysis

• 4.1. Global Aminoglycosides Market: Product Dashboard
• 4.2. Global Aminoglycosides Market: Product Movement Analysis
• 4.3. Global Aminoglycosides Market by Product, Revenue
• 4.4. Neomycin
  • 4.4.1. Neomycin market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Tobramycin
  • 4.5.1. Tobramycin market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Gentamicin
  • 4.6.1. Gentamicin market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Amikacin
  • 4.7.1. Amikacin market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Paromomycin
  • 4.8.1. Paromomycin market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Streptomycin
  • 4.9.1. Streptomycin market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Kanamycin
  • 4.10.1. Kanamycin market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Aminoglycosides Market: Route of Administration Estimates & Trend Analysis

• 5.1. Global Aminoglycosides Market: Route of Administration Dashboard
• 5.2. Global Aminoglycosides Market: Route of Administration Movement Analysis
• 5.3. Global Aminoglycosides Market by Route of Administration, Revenue
• 5.4. Injectable
  • 5.4.1. Injectable monoclonal antibodies market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Feed
  • 5.5.1. Feed market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Intra-mammary
  • 5.6.1. Intra-mammary market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Topical
  • 5.7.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Oral
  • 5.8.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Aminoglycosides Market: Application Estimates & Trend Analysis

• 6.1. Global Aminoglycosides Market: Application Dashboard
• 6.2. Global Aminoglycosides Market: Application Movement Analysis
• 6.3. Global Aminoglycosides Market by Application, Revenue
• 6.4. Skin Infection
  • 6.4.1. Skin infection market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. UTI & Pelvic Diseases
  • 6.5.1. UTI & pelvic diseases market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Veterinary
  • 6.6.1. Veterinary market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Respiratory diseases
  • 6.7.1. Respiratory diseases market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Aminoglycosides Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Pfizer Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Merck & Co. Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. AbbVie Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Teva Pharmaceutical Industries Ltd
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Cipla
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Sun Pharmaceutical Industries Ltd.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Lupin
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Aurobindo Pharma Limited
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Fresenius Kabi
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Viatris Inc.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives

관련자료